Discover More with Cryo-Fluorescence Tomography
This case study highlights the role of EMIT Imaging and Cryo-Fluorescence Tomography (CFT) in analyzing the biodistribution of a Fibroblast Activation Protein (FAP) imaging compound. This research compared biodistribution in U-87 MG tumor-bearing mice by comparing a ZW800-1 fluorescent-labeled FAP compound and a 67Cu-labeled NOTA-conjugated FAP compound of otherwise analogous structure. Animals were sacrificed at 1h or 24h post-administration for gamma counting or CFT imaging and drug uptake was determined from regions of interest from SPECT and CFT images, including tumor, knee joint, liver, and kidney. Also, the biodistribution of the ZW800-1 FAP compound from CFT was compared to the accepted SPECT and gamma counting (GC) methods. Download the case study below to learn how EMIT Imaging and CFT can help you discover more.
Download Case Study
Additional Content
Reference 1. Hesterman, Novicki, White, Stokes, Cordova, Toddes, Silva, Burke, Domarkas, Wright, Archibald, Yost, Heimann, DiMagno, Hillier, Patel, Orcutt, Amor, Tully, Babich, Hoppin. EANM 2023. Preclinical characterization of novel radiolabeled and fluorescent-labeled Fibroblast Activation Protein (FAP)-targeting ligands using gamma counting, SPECT imaging and Cryo-Fluorescence Tomography (CFT).
